Effects of body weight variation in obese kidney recipients: a retrospective cohort study by Montero Pérez, Núria et al.
O R I G I N A L A R T I C L E
Effects of body weight variation in obese kidney
recipients: a retrospective cohort study
Nuria Montero 1,2, Maria Quero 1,2, Emma Arcos3, Jordi Comas3,
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ABSTRACT
Background. Obese kidney allograft recipients have worse results in kidney transplantation (KT). However, there is lack of
information regarding the effect of body mass index (BMI) variation after KT. The objective of the study was to evaluate the
effects of body weight changes in obese kidney transplant recipients.
Methods. In this study we used data from the Catalan Renal Registry that included KT recipients from 1990 to 2011 (n ¼
5607). The annual change in post-transplantation BMI was calculated. The main outcome variables were delayed graft
function (DGF), estimated glomerular filtration rate (eGFR) and patient and graft survival.
Results. Obesity was observed in 609 patients (10.9%) at the time of transplantation. The incidence of DGF was significantly
higher in obese patients (40.4% versus 28.3%; P < 0.001). Baseline obesity was significantly associated with worse short- and
long-term graft survival (P < 0.05) and worse graft function during the follow-up (P < 0.005). BMI variations in obese patients
did not improve eGFR or graft or patient survival.
Conclusions. Our conclusion is that in obese patients, decreasing body weight after KT does not improve either short-term
graft outcomes or long-term renal function.
Keywords: epidemiology, graft function, kidney transplantation, obesity, survival analysis
INTRODUCTION
According to data from World Health Organization, the preva-
lence of obesity, described as a body mass index (BMI) 30 kg/
m2, has increased in the general population from 5% to 10% in
men and from 8% to 14% in women from 1980 to 2008.
Moreover, in 2008, 35% of adult patients (>20 years old) pre-
sented as overweight (BMI 25 kg/m2) [1]. Obesity is recognized
by the American Heart Association as a major cardiovascular
risk factor, it is frequently associated with other cardiovascular
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risk factors and it is strongly related to metabolism disorders.
Weight gain is related to elevation of arterial pressure, athero-
sclerosis and insulin resistance and has a negative effect on li-
poprotein metabolism [2].
As in the general population, there has been an incremental
increase of obesity in the end-stage renal disease (ESRD) popu-
lation and also in kidney transplant candidates during the last
decade, going from 6% to 11% in the Netherlands and from 26%
to 34% in the USA [3].
The best renal replacement therapy (RRT) in patients with
ESRD in terms of patient survival is kidney transplantation (KT).
Although complications associated with obesity in renal trans-
plantation are well proved [4, 5], some studies have shown a
similar survival benefit with transplantation compared with di-
alysis in obese and non-obese patients [5, 6]. This benefit disap-
peared in patients with a BMI >41 kg/m2 [7]. Evidence from the
published literature [8] shows better short-term patient and
graft survival and graft function and less acute rejection in
patients with a low BMI. Moreover, there were more surgical
complications in obese patients. Seventy-five to 80% of kidney
transplant recipients present at least one cardiovascular risk
factor [9]. Despite transplantation decreases the risk of death
and cardiovascular events in relation to dialysis patients, car-
diovascular events are still the leading cause of death in kidney
recipients, with an annual risk of 3.5 – 5%, 50-fold higher than
the general population [10].
There are some groups that have studied the outcomes of
KT in obese patients, but post-transplant outcomes in relation
to changes in BMI during the follow-up have not previously
been described. The main objective of this study was to analyse
the effect of basal obesity and BMI changes during the follow-up
on long-term graft and patient survival and graft function.
MATERIALS AND METHODS
After obtaining the approval of the Institutional Review Board,
we used data from the Catalan Renal Registry (RMRC). This is a
mandatory population-based registry covering 7.5 million peo-
ple that collects information on all patients with ESRD requiring
RRT in Catalonia. At the time of starting RRT and at every switch
of treatment throughout RRT, a registration form is completed.
Every year an update has to be carried out and sent to the RMRC
through the finalization of RRT, death of the patient or lost to
follow-up. In Catalonia, there are no standardized exclusion cri-
teria with regards to obesity and KT.
Between 1990 and 2011, patients who lived in Catalonia and
received a first single kidney transplant from a deceased or liv-
ing donor were considered for the analysis. Patients were fol-
lowed until death, lost to follow-up or 31 December 2015. The
median follow-up time was 9.3 years, with a maximum of 25
years. The BMI was classified in the following four groups: un-
derweight (BMI <18.5), normal weight (BMI 18.5–<25), pre-
obese (BMI 25–<30) and obese (BMI 30). The annual change in
post-transplantation BMI was calculated over the patient’s
follow-up (until December 2015). The donor variables that are
collected include sex, age, cause of death and presence of hepa-
titis C virus. The described variables of the recipient are age,
sex, primary renal disease, maximum anti-human leucocyte
antibodies (HLAs), dialysis time before transplantation and im-
munosuppression treatment during the first 6 weeks.
Transplant variables such as cold ischaemia time and HLA mis-
matches (A, B and DR) between donor and recipient were also
considered.
Comparisons between groups of patients with and without
obesity at the time of transplantation were performed by chi-
square test for categorical data and analysis of variance for con-
tinuous data (P < 0.05 was considered significant). Baseline
characteristics of the study cohort were expressed as number
and proportion or mean 6 standard deviation (SD). To evaluate
graft function and change in weight, data were only available
for those kidney grafts that survived until the first follow-up at
31 December. To evaluate the change in weight, we calculated
the percent change between basal weight and weight during the
follow-up for each year and then the mean of the different peri-
ods: [(weight at follow-up basal weight)/(basal weight)]*100. The
statistical approach to calculate the adjusted model was done
using a generalized estimating equation, which is used to esti-
mate the parameters of a generalized linear model with a possi-
ble unknown correlation between outcomes.
We assessed kidney graft survival, defined as the period
from transplant date until graft loss or patient death, whichever
came first. Cumulative incidence function (CIF) were used to
calculate the unadjusted incidence of graft survival (1-CIF) and
patient survival during transplantation, considering patient
death with functioning graft and graft loss as competing events,
respectively. We also calculated the adjusted risk of patient
death with a functioning graft and the adjusted risk of graft loss
by means of competing risks regression, considering graft fail-
ure and patient death with a functioning graft as a competing
event, respectively. The model was calculated and adjusted for
BMI at the moment of KT, loss of weight between transplanta-
tion and overall follow-up, age and gender of the recipient, age
of the donor, pre-transplantation dialysis time, type of KT, pres-
ence of diabetes mellitus, cardiovascular comorbidities (ischae-
mic heart disease, cardiac failure, cardiac conduction disorders,
cerebrovascular disease or peripheral vascular disease), period
of time for transplantation (1990–2000 and 2001–11) and treat-
ment with tacrolimus. The final model was chosen using the
Akaike information criterion, which assumes that the lower the
values, the better the value of the model.
Statistical analyses were performed using Stata software
version 13 (StataCorp, College Station, TX, USA).
RESULTS
We followed the Strengthening the Reporting of
Observational Studies in Epidemiology guidelines to report
this observational study. In this population-based study, we
included adult recipients living in Catalonia who had received
a first deceased (n ¼ 5415) or living donor kidney transplant
(n ¼ 568) between January 1990 and December 2011 (n ¼ 5983)
whose weight and height at transplantation were known
(n ¼ 5607 patients).
Characteristics of included recipients
Of the 5607 patients, 194 (3.5%) were underweight, 2904 (51.8%)
normal weight, 1900 (33.9%) pre-obese and 609 (10.9%) were
obese. Basal characteristics of donors and recipients were com-
pared between the obese and non-obese groups (Table 1). We
found some differences between groups: more obese recipients
were transplanted during the 2001–11 period compared with the
previous decade (P < 0.001), obese patients have more comor-
bidities (P < 0.001) and there were younger donors (P < 0.001)
and recipients (P < 0.001) in the non-obese group. When we
analysed the percentage of weight change during the follow-up,
we found a weight gain in the majority of patients of all groups
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Table 1. Characteristics of included recipients depending on BMI group
Characteristics Obese (n¼ 609) Pre-obese (n¼ 1900) Normal weight (n¼ 2904) Underweight (n¼ 194) P-value
BMI (mean 6 SD) 33.2 6 3.3 27.1 6 1.4 22.3 6 1.7 17.3 6 1.0
Recipient variables
Primary renal disease
Glomerular 144 (23.6) 494 (26.0) 847 (29.2) 62 (32) <0.001
Polycystic 76 (12.5) 306 (16.1) 476 (16.4) 19 (9.8) –
Interstitial 77 (12.6) 239 (12.6) 434 (14.9) 29 (14.9) –
Vascular 92 (15.1) 239 (12.6) 294 (10.1) 17 (8.8) –
Diabetes 84 (13.8) 143 (7.5) 139 (4.8) 7 (3.6) –
Others 25 (4.1) 133 (7.0) 251 (8.6) 29 (14.9) –
Unknown 111 (18.2) 346 (18.2) 463 (15.9) 31 (16.0) –
Sex
Male 333 (54.7) 1274 (67.1) 1851 (63.7) 65 (33.5) <0.001
Age (years)
<45 130 (21.3) 397 (20.9) 1123 (38.7) 121 (62.4) <0.001
45–54 160 (26.3) 501 (26.4) 679 (23.4) 30 (15.5) –
55–64 196 (32.2) 593 (31.2) 700 (24.1) 32 (16.5) –




144 (27.7) 353 (22.5) 392 (16.8) 23 (15.2) <0.001
Diabetes mellitus 221 (36.7) 408 (21.7) 399 (13.8) 18 (9.3) <0.001
Hypertension 352 (79.1) 865 (71.7) 115 (63.0) 64 (56.1) <0.001
Maximum CDC (%)
0–10 503 (83.4) 1612 (85.1) 2399 (83.1) 157 (81.3) 0.307
11–50 74 (12.3) 221 (11.7) 364 (12.6) 30 (15.5) –
>50 26 (4.3) 61 (3.2) 124 (4.3) 6 (3.1) –
Dialysis time before KT
(years)
1 156 (25.6) 431 (22.7) 718 (24.7) 47 (24.2) 0.610
1–2 150 (24.6) 511 (26.9) 727 (25.0) 50 (25.8) –
>2 303 (49.8) 958 (50.4) 1459 (50.2) 97 (50.0) –
Donor variables
Donor type
Deceased 541 (88.8) 1756 (92.4) 2630 (90.6) 173 (89.2) 0.022
Living donor 68 (11.2) 144 (7.6) 274 (9.4) 21 (10.8)
Sex
Male 351 (57.9) 1123 (59.5) 1734 (60.1) 116 (59.8) 0.790
Age (years)
<45 173 (28.5) 576 (30.5) 1152 (40.0) 104 (54.2) <0.001
45–54 147 (24.2) 394 (20.9) 651 (22.6) 39 (20.3) –
55–64 156 (25.7) 492 (26.1) 615 (21.3) 28 (14.6) –
65 131 (21.6) 425 (22.5) 465 (16.1) 21 (10.9) –
Hepatitis C virus positive 8 (1.6) 23 (1.5) 46 (2.0) 6 (3.9) 0.160
Transplant procedure
Period
1990–2000 167 (27.4) 719 (37.8) 1245 (42.9) 83 (42.8) <0.001
2001–11 442 (72.6) 1181 (62.2) 1659 (57.1) 111 (57.2) –
Cold ischaemia time (h)
0–18 328 (59.7) 959 (57.7) 1526 (60.5) 101 (62.0) 0.392
19–24 171 (31.1 529 (31.8) 739 (29.3) 42 (25.8) –
>24 50 (9.1) 174 (10.5) 257 (10.2) 20 (12.3) –
Immunosuppression treat-
ment during the first
6 weeks
Tacrolimus 314 (51.5) 876 (48.9) 1336 (48.3) 94 (50.5) 0.051
Cyclosporine 177 (30.8) 682 (38.1) 1122 (40.7) 79 (42.5) <0.001
Mycophenolate 449 (78.1) 1257 (70.1) 1857 (67.2) 117 (62.9) <0.001
Basiliximab/daclizumab 218 (38.2) 549 (30.8) 687 (25.1) 41 (22.3) <0.001
Number of matches
between donor and recip-
ient (HLA-A, HLA-B and
HLA-DR)
(continued)
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with a low percentage of patients changing the basal BMI cate-
gory to obese (Table 2 and Supplementary data, Table S1).
However, there were differences between groups, with small
changes in weight in the obese group, a moderate increase in
normal and pre-obese patients and a large increase in weight in
the underweight group, especially during the first 2 years.
Afterwards, the trend of weight change remained stable in all
groups (Supplementary data, Figure S1 and Table S2).
Delayed graft function
Delayed graft function (DGF) was defined as the need for dialy-
sis in first week, excluding the first 24 h. A greater incidence of
DGF was found in the cohort of obese recipients (40.4), com-
pared with 17.6% in underweight (n ¼ 30), 28.3% in normal
weight (n ¼ 750) and 32.4% in pre-obese (n ¼ 568) (Table 2).
Graft function
To evaluate graft function, we only had data for those kidney
grafts that survived at least until the first post-transplantation
year (n ¼ 5262). During the first 5 years of follow-up, all the in-
cluded population except the underweight group tended to im-
prove eGFR [Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula]. In the underweight patients,
we found an initial decline in eGFR, but afterwards they main-
tained better graft function during the follow-up compared with
other groups (P < 0.001). On the other hand, obese patients had
the worst eGFR during the follow-up (P < 0.001) (Supplementary
data, Figure S1 and Table S2).
In obese patients, we did not find any beneficial effect of
weight change or after adjusting for other covariables (Table 3).
In this cohort of recipients, factors that improved the value of
eGFR were male sex or age <45 years, receiving a kidney from a
donor <65 years of age and immunosuppression with tacroli-
mus. On the other hand, those obese patients who developed
DGF had worse eGFR in the multivariate analysis [mean differ-
ence 5.90 mL/min/1.73 m2 (range8.66 to 3.14), P < 0.05]
(Table 3).
Graft survival
Short-term graft survival was worse in underweight (89.8%) and
obese patients (91.1%) compared with pre-obese (93%) or normal
weight patients (94.6%) (P ¼ 0.043) (Supplementary data, Figure
S2). The adjusted subhazard ratio (SHR) showed a statistically
significant increased risk of graft loss in the underweight [SHR
2.28 (95% CI 1.27–4.12); P < 0.001] and obese group [SHR 1.67
(95% CI 1.23–2.28); P < 0.001] compared with the normal group.
Presenting with DGF significantly increased the risk of graft loss
[SHR 2.91 (95% CI 2.32–3.64); P < 0.001] (Table 4).
We found 363 graft losses during the first year. The majority
of them (54.5%) were due to vascular thrombosis not related to
immunological rejection, graft infection or primary non-
function (Table 2).
The median graft survival time was 8.6 years, with a maxi-
mum value of 25 years. Until the end of follow-up, taking into
account death as a competing risk, graft survival was also worse
in obese (68%) and underweight (62.7%) patients compared with
normal weight (69.5%) and pre-obese (71.2%) patients (P ¼ 0.003)
(Supplementary data, Figure S2). When the basal weight cate-
gory was adjusted to other factors, obesity still increased graft
loss [SHR 1.29 (95% CI 1.08–1.54); P < 0.05] (Table 4).
In obese recipients, when we evaluated the effect of post-
transplant weight change on graft survival, we did not find any
benefit of losing weight (P ¼ 0.526). When we performed the
multivariate model we found no benefit [1–10% loss: SHR 1.30
(95% CI 0.66–2.57), if >10% loss: SHR 0.98 (95% CI 0.44–2.18)], nor
worse outcomes if weight increased [SHR 1.68 (95% CI 0.91–3.12)]
(Figure 1, Supplementary data, Table S2).
Patient survival
Patient survival considering the entire cohort of patients was
worse in the pre-obese group (P < 0.001) (Supplementary data,
Figure S3 and Table S5). When the hazard ratio (HR) was ad-
justed for other variables in a multivariate analysis, this effect
disappeared (Table 5). When we evaluated the effect of weight
change on obese patient mortality in a multivariate analysis,
changes in weight had no impact on patient mortality [1–10%
loss: SHR 1.79 (95% CI 0.79–4.06), >10% loss: SHR 1.24 (95% CI
0.48–3.16) and weight gain >1%: SHR 1.18 (95% CI 0.54–2.54)]
(Figure 2 and Supplementary data, Table S3).
DISCUSSION
Although transplantation is the best option for RRT in terms of
patient survival [5], one of the main limitations of access to
waiting lists is overweight. The main objective of this study was
to analyse the effect of basal obesity and BMI changes during
the follow-up and their relation with graft function and graft
and patient survival.
In a prospective cohort of the French Renal Epidemiology
and Information Network Registry [11], the authors did a multi-
variate analysis (evaluating also age, diabetes, congestive heart
failure, cancer, albuminaemia level and type of dialysis) and
they found that patients with a BMI 31 kg/m2 at the start of di-
alysis were less likely to receive a kidney transplant and this
Table 1. Continued
Characteristics Obese (n¼ 609) Pre-obese (n¼ 1900) Normal weight (n¼ 2904) Underweight (n¼ 194) P-value
0 44 (7.3) 118 (6.2) 147 (5.1) 14 (7.3) 0.098
1 135 (22.4) 385 (20.3) 653 (22.6) 34 (17.6) –
2 210 (34.9) 689 (36.4) 985 (34.1) 67 (34.7) –
3 160 (26.6) 508 (26.8) 847 (29.3) 60 (31.1) –
4 53 (8.8) 194 (10.2) 255 (8.8) 18 (9.3) –
Values presented as n (%).
aIschaemic heart disease, cardiomyopathy, cardiac conduction disorders, cerebrovascular disease or vascular disease. CDC, classic complement-dependent
cytotoxicity crossmatch technique.
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probability increased as the weight decreased [HR 1.09 (95% CI
1.06–1.10)]. There are four major KT guidelines regarding this
cardiovascular risk factor. Both the UK Renal Association [7] and
Kidney Health Australia– Caring for Australasians with Renal
Impairment) [12] state that although obesity is not a formal con-
traindication of KT, the benefits of KT are doubtful in individu-
als with a BMI 40. European Renal Best Practice guidelines [13]
only recommend weight loss in obese patients. The Kidney
Disease: Improving Global Outcomes guidelines [14] state that
weight reduction before the surgical procedure did not provide
as much beneficial effect as could be expected in general popu-
lation, so they did not make any specific recommendation
about the topic. There are many studies that have evaluated the
outcomes in KT related to weight, but this is the first one that
evaluates post-transplant outcomes in obese patients in rela-
tion to long-term changes in BMI during the follow-up.
In our Catalan cohort, we found 10.9% of patients were obese
before KT. This prevalence is quite different from other regis-
tries; for example, the United Network for Organ Sharing data
showed a prevalence of 30% [15] and a group published data
from the Australia and New Zealand renal registry estimating
24% of patients were obese [16].
There is a relationship between obesity and an increase in
DGF. This incremental risk could be explained because of the
more complex surgical procedure, which consequently brings a
longer duration of cold ischaemia time [17]. Lafranca et al. [8]
published a recent meta-analysis including 30 studies (15 262
recipients) that showed an overall risk ratio of 1.52 (95% CI 1.35–
1.72; P < 0.001). There are two concomitant publications, Hill et
al. [4] and Nicoletto et al. [18], that found similar results. In a
newly published study, the authors showed the beneficial
effects of laparoscopic sleeve gastrectomy before KT in patients
that met the criteria for bariatric surgery (BMI 40kg/m2 or 35
kg/m2 with two or more obesity-related conditions) [19]. They
found less DGF and better eGFR in those patients who under-
went gastrectomy before KT compared with a matched control
group. This finding is similar in our data, with the highest inci-
dence of DGF in the obese group (40.4%), remaining statistically
significant after multivariate analysis. Apart from surgical fac-
tors, the higher metabolic demand in obese patients could also
contribute to the higher incidence of DGF in this cohort.
The only published study that shows data about GFR is one
by Moreira et al. [20]. It concludes that pre-transplant over-
weight and obese patients present significantly lower GFR at 5
years. In our study, when data were analysed for subgroups, we
found that obesity was related with worse eGFR and that weight
changes in the obese group did not modify eGFR. This informa-
tion has not been previously reported. Our eGFR data were ana-
lysed based on the CKD-EPI equation that is based on serum
creatinine, which is related with muscle mass and is also a con-
tributor to BMI. It has to be considered equation that under-
weight patients have lower muscle mass and therefore better
eGFR measured by the CKD-EPI equation. In support of this in-
terference, there were no differences in graft survival between
groups. DGF impacted negatively on long-term eGFR in obese
patients. On the other hand, underweight recipients that
remained with a functioning graft had a better eGFR during the
follow-up compared with the other groups. This effect could be
explained because obese recipients have higher rates of hyper-
tension, post-transplant diabetes and hyperfiltration due to an
unpaired ratio between donor nephron mass and recipient BMI
that cannot be changed later with a weight loss.
In our study, when we analysed all the included population,
we found increased first-year graft loss in underweight and
obese patients, which can be explained by a worse basal clinical
situation to receive a kidney transplant. In the case of obese
recipients, this increased weight brings greater surgical difficul-
ties and more complications related to it. We also evaluated
change in weight of obese patients and show that these weight
changes did not change graft survival. These results have been
adjusted by risk factors such as sex of the recipient, type of do-
nor, age of the donor and recipient, time in dialysis before trans-
plantation, DGF or use of tacrolimus. Those short-term, obesity-
related complications may jeopardize the possible long-term
benefits of losing weight. The idea of worse short- and long-
term graft survival in patients with higher BMI is well estab-
lished, but the finding of the absence of a beneficial effect of los-
ing weight has never been published before. This short-term
effect could be explained because of more surgical complica-
tions, wound infections and a higher risk of DGF.
KT brings higher patient survival compared with haemodial-
ysis in all patients, including obese patients. There are three re-
cent meta-analyses that evaluated this outcome post-KT and
show different results in patient survival [8, 18]. These differen-
ces could be explained because survival was evaluated at differ-
ent time points (1, 2, 3 or 5 years of follow-up) or because the
selection of the included studies is different. Perhaps the year of
publication may also explain these differences; as Nicoletto et
al. [18] have already described, they found better survival in
obese patients in reports published after 2003. Similar to graft
survival, patient survival can be negatively affected by cardio-
vascular risk factors. All the published studies except one used
Table 3. Multivariate model evaluating the change in the mean
value of the CKD-EPI equation (mL/min/1.73 m2) depending on the
change in BMI in obese patients
Variables
Change in mean value (range) of
CKD-EPI (mL/min/1.73 m2)
Percentage of weight change
Gain/loss <1% Reference
Loss 10–1% 1.21 (0.68–3.10)
Loss >10% 0.63 (1.87–3.13)
Gain >1% 0.86 (2.51–0.79)
Sex
Male Reference
Female 3.39 (6.04 to 0.73)*
Donor age (years)
<45 Reference
45–54 13.22 (16.83 to 9.60)*
55–64 16.04 (20.02 to 12.05)*
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Table 4. Risk factors for graft loss
Variables
Graft loss











Underweight 1.95 (1.23–3.11)* 2.28 (1.27–4.12)* 1.39 (1.09–1.78)* 1.39 (1.05–1.84)*
Pre-obese 1.30 (1.03–1.63)* 1.11 (0.83–1.48) 0.97 (0.87–1.08) 0.93 (0.82–1.05)
Obese 1.67 (1.23–2.28)* 1.59 (1.11–2.26)* 1.22 (1.04–1.44)* 1.29 (1.08–1.54)*
Period
1990–2000 Reference – – –
2001–11 0.75 (0.62–0.91)* 1.41 (1.04–1.91)* 0.67 (0.61–0.74)* 0.96 (0.84–1.08)
Recipient age (years)
<45 Reference – – –
45–54 1.08 (0.81–1.42) 0.81 (0.54–1.19) 0.84 (0.75–0.95)* 0.69 (0.59–0.79)*
55–64 1.19 (0.92–1.55) 0.90 (0.60–1.34) 0.80 (0.71–0.90)* 0.58 (0.49–0.68)*
65 1.56 (1.18–2.07)* 1.09 (0.69–1.73) 0.79 (0.68–0.92)* 0.49 (0.39–0.60)*
Maximum CDC (%)
0–10 Reference – – –
11–50 1.62 (1.24–2.11)* 1.55 (1.10–2.18)* 1.31 (1.14–1.49)* 1.26 (1.08–1.47)*
>50 2.52 (1.77–3.60)* 3.02 (1.94–4.72)* 1.69 (1.37–2.09)* 1.71 (1.35–2.16)*
Tacrolimus
No Reference – – –
Yes 0.60 (0.48–0.75)* 0.63 (0.48–0.85)* 0.58 (0.52–0.64)* 0.63 (0.55–0.71)*
Donor type
Deceased Reference – – –
Living 0.39 (0.24–0.64)* 0.75 (0.39–1.45) 0.53 (0.41–0.66)* 0.62 (0.46–0.84)*
Donor age (years)
<45 Reference – – –
45–54 1.25 (0.95–1.64) 1.37 (0.95–1.98) 1.17 (1.03–1.32)* 1.45 (1.25–1.68)*
55–64 1.21 (0.92–1.59) 1.38 (0.93–2.07) 1.27 (1.12–1.43)* 1.82 (1.55–2.13)*
65 1.58 (1.20–2.07)* 1.81 (1.16–2.81)* 1.37 (1.20–1.57)* 2.45 (2.01–2.98)*
DGF
No Reference – – –
Yes 2.91 (2.32–3.64)* 2.83 (2.18–3.69)* 1.57 (1.41–1.74)* 1.47 (1.31–1.65)*
*P<0. 05.
CDC, classic complement-dependent cytotoxicity crossmatch technique.
FIGURE 1: Comparison of graft survival curves according to variations in weight in obese patients. In the obese patients, weight change did not modify graft survival.
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BMI data from the pre-transplant period to classify the patients
[3]. That study takes into account weight changes and post-
transplant BMI. They described that both pre-transplant and es-
pecially 1-year post-transplantation obesity brings a higher risk
for mortality and graft failure and that weight gain 1 year after
transplantation brings a higher risk of death and graft failure in-
dependent of pre-transplant BMI. In our experience, after con-
sidering all confounding risk factors, the weight change during
follow-up did not have any effect on patient survival.
Our study has several strengths and limitations. In this
study, we report long-term follow-up, with a median of 8.6 years
and a maximum of 25 years, and it is the only study with base-
line and follow-up data for BMI variations. The main limitation
is the retrospective nature of the routine data obtained through
the Catalonian Renal Registry. Although multiple confounding
factors were considered, there may be unmeasured residual
confounders not collected by the registry that could also have
contributed to the study findings.
In conclusion, in this large retrospective cohort study with
long-term follow-up, we show worse renal function and short-
term graft survival outcomes in obese patients. The possible
long-term benefits of losing weight for graft survival and graft
function may be jeopardized by short-term obesity-related com-
plications, particularly DGF. The implication for practice of
these findings is that it is necessary to focus on losing weight
before KT and not after.
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Underweight 0.71 (0.49–1.02) 1.29 (0.84–1.96)
Pre-obese 1.29 (1.14–1.46)* 0.90 (0.78–1.03)
Obese 1.20 (0.99–1.46) 0.89 (0.71–1.1)
Recipient sex
Male Reference –
Female 0.81 (0.72–0.9)* 0.72 (0.63–0.83)*
Recipient age (years)
<45 Reference –
45–54 3.08 (2.49–3.8)* 2.87 (2.17–3.79)*
55–64 6.18 (5.08–7.51)* 6.05 (4.67–7.83)*
65–69 9.53 (7.7–11.81)* 9.59 (7.25–12.67)*
70 11.47 (9.1–14.45)* 13.11 (9.83–17.48)*
Any cardiovascular morbidity*
No Reference –
Yes 1.96 (1.71–2.24)* 1.28 (1.11–1.48)*
Dialysis time before KT (years)
1 Reference
1–2 1.67 (1.41–1.98)* 1.34 (1.11–1.63)*
>2 2.00 (1.72–2.33)* 1.43 (1.2–1.72)*
*P<0. 05.
FIGURE 2: Comparison of patient survival curves according to variations in weight in obese patients. In the obese patients, survival was not different depending on the
weight change category.
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